clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-96-98clinvest-537Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность применения дексаметазона у пациентов с COVID-19Dexamethasone use in patients with COVID-19https://orcid.org/0000-0003-0623-7263ОтделеновВ. А.OtdelenovV. A.

Отделенов Виталий Александрович – доцент кафедры клинической фармакологии и терапии. SPIN-код: 8357-5770

Москва

Otdelenov Vitaly A. – Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8357-5770

Moscow

https://orcid.org/0000-0002-9307-4994МирзаевК. Б.MirzaevK. B.

Мирзаев Карин Бадавиевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8308-7599

Москва

Mirzaev Karin B. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8308-7599

Moscow

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian Federation20202810202004SФармаCOVID9698Copyright © Отделенов В.А., Мирзаев К.Б., Сычёв Д.А., 20202020Отделенов В.А., Мирзаев К.Б., Сычёв Д.А.Otdelenov V.A., Mirzaev K.B., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/537

Дексаметазон может быть рассмотрен для применения у пациентов с тяжёлыми формами COVID-19 с целью снижения смертности.

Dexamethasone may be used for mortality reduction in patients with severe COVID-19

коронавирусдексаметазонCOVID-19coronavirusdexamethasoneCOVID-19ReferencesГосударственный реестр лекарственных средств. Дексаметазон. Инструкция по медицинскому применению. [Электронный ресурс]. Доступно по: https://clck.ru/RBfe6 Ссылка активна на 26.06.2020State register of medicines. Dexamethasone. Instructions for medical use. (In Russ). Доступно по: https://clck.ru/RBfe6 Ссылка активна на 26.06.2020Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) 7-е изд., Москва: Министерство здравоохранения Российской Федерации, 2020. Доступно по: https://clck.ru/Nodnb Ссылка активна на 04.06.2020The provisional guidelines. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) 7th ed., Moscow: Ministry of health of the Russian Federation, 2020 (In Russ). Доступно по: https://clck.ru/Nodnb Ссылка активна на 04.06.2020Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006 Sep;3(9):e343. DOI: 10.1371/journal.pmed.003034Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006 Sep;3(9):e343. DOI: 10.1371/journal.pmed.003034Arabi YM et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. DOI: 10.1164/rccm.201706-1172OC3Arabi YM et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. DOI: 10.1164/rccm.201706-1172OC3Oxford University News Release: Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. 2020.Oxford University News Release: Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. 2020.Horby P et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. Cold Spring Harbor Laboratory Press, 2020. P. 2020.06.22.20137273. DOI: 10.1056/NEJMoa2021436Horby P et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. Cold Spring Harbor Laboratory Press, 2020. P. 2020.06.22.20137273. DOI: 10.1056/NEJMoa2021436Judith A et al. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (NIH). NIH. 2020. Vol. 2019. P. 124.Judith A et al. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (NIH). NIH. 2020. Vol. 2019. P. 124.Fernandez-Cruz A et al. Impact of glucocorticoid treatment in SARSCOV-2 infection mortality: a retrospective controlled cohort study. medRxiv. American Society for Microbiology Journals, 2020. P. 2020.05.22.20110544.Fernandez-Cruz A et al. Impact of glucocorticoid treatment in SARSCOV-2 infection mortality: a retrospective controlled cohort study. medRxiv. American Society for Microbiology Journals, 2020. P. 2020.05.22.20110544.Wu C et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. American Medical Association, 2020.Wu C et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. American Medical Association, 2020.Brigham and Women’s Hospital COVID-19 Protocols [Internet]. [cited 2020 June 27]; Available from: https://covidprotocols.org/Brigham and Women’s Hospital COVID-19 Protocols [Internet]. [cited 2020 June 27]; Available from: https://covidprotocols.org/Massachusetts General Hospital (MGH) COVID-19 Treatment Guidance [Internet]. [cited 2020 June 26]; Available from: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID19-treatment-guidance.pdfMassachusetts General Hospital (MGH) COVID-19 Treatment Guidance [Internet]. [cited 2020 June 26]; Available from: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID19-treatment-guidance.pdfStatement from the National COVID-19 Clinical Evidence Taskforce on media release of results of dexamethasone arm of the UK RECOVERY Trial. 2020.Statement from the National COVID-19 Clinical Evidence Taskforce on media release of results of dexamethasone arm of the UK RECOVERY Trial. 2020.UW Medicine COVID-19 Resource Site [Internet]. [cited 2020 June 28]; University of Washington. 2020. Available from: https://covid-19.uwmedicine.org/Pages/default.aspx (accessed: 28.06.2020).UW Medicine COVID-19 Resource Site [Internet]. [cited 2020 June 28]; University of Washington. 2020. Available from: https://covid-19.uwmedicine.org/Pages/default.aspx (accessed: 28.06.2020).

The authors declare that there are no conflicts of interest present.